Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has included SZJ0107 tablets, developed by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd., in the “Care Plan Extension” pilot project for encouraging innovative drug R&D for rare diseases, targeting spinocerebellar ataxia (SCA), the agency announced in a formal inclusion notice dated Sept 4, 2026.
Program Snapshot
| Attribute | Detail |
|---|---|
| Program | Care Plan Extension (Rare Disease Innovative Drug R&D Incentive Pilot) |
| Product | SZJ0107 Tablets |
| Applicant | Anhui Sanzhijian Pharmaceutical Technology Co., Ltd. |
| Indication | Spinocerebellar ataxia (SCA) |
| Notice type | Formal pilot inclusion (not a public consultation) |
| Issuing body | Center for Drug Evaluation (CDE), NMPA |
| Date | Sept 4, 2026 |
Clinical Context
Spinocerebellar ataxia refers to a group of hereditary neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connections, leading to worsening coordination of gait, speech and limb movements. More than 40 genetic subtypes have been identified, with SCA3 (Machado-Joseph disease) the most prevalent form in China. No disease-modifying therapy is currently approved for SCA—treatment remains supportive—and the condition is listed in China’s official rare disease catalog, with estimated prevalence of roughly 3 to 6 per 100,000. The absence of any approved therapy and the progressive, disabling nature of the disease place SCA among the highest-unmet-need areas in neurology.
Market Impact Analysis
Unlike proposal-stage listings that open a public comment window, this notice confirms SZJ0107’s formal inclusion in the Care Plan Extension pilot—meaning the asset immediately qualifies for the program’s incentive package, which typically encompasses enhanced regulatory communication, rolling data submissions and potential priority pathways for rare disease candidates.
For Anhui Sanzhijian, a regional pharmaceutical technology company, the designation elevates a niche neurology asset into China’s premier rare disease fast-track framework, improving both development economics and partnering visibility. SCA represents a strategically underserved space: global developers have historically deprioritized it due to small patient populations and genetically heterogeneous trial designs, yet recent advances in genetic and targeted therapeutic approaches are reviving interest worldwide. By channeling a domestic SCA candidate into the pilot, CDE is signaling intent to build indigenous capability in rare neurodegenerative diseases rather than rely on imported therapies.
The inclusion also adds momentum to the Care Plan Extension cohort itself, demonstrating that the program is actively admitting CNS and neurodegenerative indications beyond its initial focus areas, which could encourage additional submissions from small and mid-cap Chinese biotechs pursuing orphan neurology assets.
Forward-Looking Statement
Industry observers expect SZJ0107 to advance clinical development under the pilot’s enhanced regulatory support, with the formal inclusion potentially compressing trial-to-review timelines if the program generates positive efficacy and safety data in SCA populations. Progress toward registration would mark a potential first-in-class outcome for spinocerebellar ataxia in China, establishing proof-of-concept for the Care Plan Extension in hereditary ataxias and opening pathways for related neurodegenerative rare disease candidates. The inclusion further reinforces China’s strategic push to localize rare disease drug innovation and expand treatment options for patients currently limited to supportive care. Further details on SZJ0107’s development stage and trial plans are expected to emerge from the applicant as the program advances.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/074dea77e97b316fc1c783cc0091937b